 OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to gender, disease stage IV vs other, geographic location US vs Western Europe and Canada vs the rest of the world, and prior brain metastases yes vs no. Patients are randomized to 1 of 2 treatment arms. 